Short Communication

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

Gan, H.K.
Millward, M.
Jalving, M.
Garrido-Laguna, I.
Lickliter, J.D.
Schellens, J.H.
Lolkema, M.P.
Herpen, C.M.L. van
Hug, B.
Tang, L.
O'Connor-Semmes, R.
Gagnon, R.
Ellis, C.
Ganji, G.
Matheny, C.
Drilon, A.

January 2021

BACKGROUND: GSK2849330, an anti-HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signal...

A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors

Hellmann, Matthew David
Shimizu, Toshio
Doi, Toshihiko
Hodi, F. Stephen
Rottey, Sylvie
Aftimos, Philippe Georges
Liu, Zhuqing Tina
de Mendizabal, Nieves Velez
Szpurka, Anna M.
Piao, Yongzhe
Vangerow, Burkhard
Gandhi, Leena
Leow, Ching Ching

January 2019

TPS2654 Background: Programmed cell death 1 immune checkpoint inhibitors (anti-PD-1, anti-PD-L1) ha...

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Ben Tran
Richard D. Carvajal
Aurelien Marabelle
Sandip Pravin Patel
Patricia M. LoRusso
Erik Rasmussen
Gloria Juan
Vijay V. Upreti
Courtney Beers
Gataree Ngarmchamnanrith
Patrick Schöffski

September 2018

Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokin...

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.

Saulnier-Sholler, Giselle
Duda, Dan G
Bergendahl, Genevieve
Ebb, David
Snuderl, Matija
Laetsch, Theodore W
Michlitsch, Jennifer
Hanson, Derek
Isakoff, Michael S
Bielamowicz, Kevin
Kraveka, Jacqueline M
Ferguson, William
Carmeliet, Peter
De Deene, A
Gijsen, Lore
Jain, Rakesh K

September 2022

PurposePlacental growth factor (PlGF) and its receptor neuropilin 1 are elevated in malignant embryo...

PHASE I STUDIES

Zev A. Wainberg

January 2013

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subject...

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Chiorean, E.
Sweeney, C.
Youssoufian, H.
Qin, A.
Dontabhaktuni, A.
Loizos, N.
Nippgen, J.
Amato, R.

January 2014

PURPOSE: The platelet-derived growth factor receptor (PDGFR) has an important role in tumorigenesis ...

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

Tran, Ben
Carvajal, Richard D
Marabelle, Aurelien
Patel, Sandip Pravin
LoRusso, Patricia M
Rasmussen, Erik
Juan, Gloria
Upreti, Vijay V
Beers, Courtney
Ngarmchamnanrith, Gataree
Schoffski, Patrick

September 2018

BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, p...

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

L.W. Goff
R.B. Cohen
J.D. Berlin
F.G. De Braud
A. Lyshchik
C. Noberasco
F. Bertolini
M. Carpentieri
C.G. Stampino
A. Abbattista
E. Wang
H. Borghaei

May 2016

Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II do...

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

Wagner, AJ
Kindler, H
Gelderblom, H
Schöffski, Patrick
Bauer, S
Hohenberger, P
Kopp, H-G
Lopez-Martin, JA
Peeters, M
Reichardt, P
Qin, A
Nippgen, J
Ilaria, RL
Rutkowski, P

March 2017

This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously...

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Aftimos, Philippe
Van Rompaey, Luc
Michotte, Jean-Marie
Silence, Karen
Hultberg, Anna
Gandini, Domenica
De Haard, Hans
Ribrag, Vincent
Peeters, Michel
Thibault, Alain
Leupin, Nicolas
Rolfo, Christian
Awada, Ahmad
Rottey, Sylvie
Offner, Fritz
Bron, Dominique
Maerevoet, Marie
Soria, Jean-Charles
Moshir, Mahan
Dreier, Torsten

November 2017

Purpose: The purpose of this study was to evaluate safety, pharmacokinetics, pharmacodynamics, and p...

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.

Naing, Aung
Gainor, Justin F
Gelderblom, Hans
Forde, Patrick M
Butler, Marcus O
Lin, Chia-Chi
Sharma, Sunil
Ochoa de Olza, Maria
Varga, Andrea
Taylor, Matthew H
Schellens, Jan H M
Wu, Hongqian
Sun, Haiying
Silva, Antonio P
Faris, Jason
Mataraza, Jennifer
Cameron, Scott
Bauer, Todd M

March 2020

BACKGROUND: Spartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD...

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Reynolds, Kerry Lynn
Bedard, Philippe L
Lee, Se-Hoon
Lin, Chia-Chi
Tabernero, Josep
Alsina, Maria
Cohen, Ezra
Baselga, José
Blumenschein, George
Graham, Donna M
Garrido-Laguna, Ignacio
Juric, Dejan
Sharma, Sunil
Salgia, Ravi
Seroutou, Abdelkader
Tian, Xianbin
Fernandez, Rose
Morozov, Alex
Sheng, Qing
Ramkumar, Thiruvamoor
Zubel, Angela
Bang, Yung-Jue

December 2017

BackgroundHuman epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal grow...

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Jennifer Mataraza
Todd M Bauer
Justin F Gainor
Sunil Sharma
Maria Ochoa de Olza
Jan H M Schellens
Hongqian Wu
Haiying Sun
Antonio P Silva
Jason Faris
Scott Cameron

June 2020

BackgroundSpartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1...

A Phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Seroutou, Abdelkader
Tian, Xianbin
Fernandez, Rose
Morozov, Alex
Sheng, Qing
Ramkumar, Thiruvamoor
Zubel, Angela

January 2017

Background: Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal g...

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Coveler, Andrew L
Smith, David C
Phillips, Tycel
Curti, Brendan D
Goel, Sanjay
Mehta, Amitkumar N
Kuzel, Timothy M
Markovic, Svetomir N
Rixe, Olivier
Bajor, David L
Gajewski, Thomas F
Gutierrez, Martin
Lee, Hun Ju
Gopal, Ajay K
Caimi, Paolo
Heath, Elisabeth I
Thompson, John A
Ansari, Sahar
Jacquemont, Celine
Topletz-Erickson, Ariel
Zhou, Peigen
Schmitt, Michael W
Grilley-Olson, Juneko E

June 2023

BACKGROUND: SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG METHODS: SEA-C...

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

Gan, H.K.
Millward, M.
Jalving, M.
Garrido-Laguna, I.
Lickliter, J.D.
Schellens, J.H.
Lolkema, M.P.
Herpen, C.M.L. van
Hug, B.
Tang, L.
O'Connor-Semmes, R.
Gagnon, R.
Ellis, C.
Ganji, G.
Matheny, C.
Drilon, A.

January 2021

BACKGROUND: GSK2849330, an anti-HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signal...

A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors

Hellmann, Matthew David
Shimizu, Toshio
Doi, Toshihiko
Hodi, F. Stephen
Rottey, Sylvie
Aftimos, Philippe Georges
Liu, Zhuqing Tina
de Mendizabal, Nieves Velez
Szpurka, Anna M.
Piao, Yongzhe
Vangerow, Burkhard
Gandhi, Leena
Leow, Ching Ching

January 2019

TPS2654 Background: Programmed cell death 1 immune checkpoint inhibitors (anti-PD-1, anti-PD-L1) ha...

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Ben Tran
Richard D. Carvajal
Aurelien Marabelle
Sandip Pravin Patel
Patricia M. LoRusso
Erik Rasmussen
Gloria Juan
Vijay V. Upreti
Courtney Beers
Gataree Ngarmchamnanrith
Patrick Schöffski

September 2018

Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokin...

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.

Saulnier-Sholler, Giselle
Duda, Dan G
Bergendahl, Genevieve
Ebb, David
Snuderl, Matija
Laetsch, Theodore W
Michlitsch, Jennifer
Hanson, Derek
Isakoff, Michael S
Bielamowicz, Kevin
Kraveka, Jacqueline M
Ferguson, William
Carmeliet, Peter
De Deene, A
Gijsen, Lore
Jain, Rakesh K

September 2022

PurposePlacental growth factor (PlGF) and its receptor neuropilin 1 are elevated in malignant embryo...

PHASE I STUDIES

Zev A. Wainberg

January 2013

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subject...

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Chiorean, E.
Sweeney, C.
Youssoufian, H.
Qin, A.
Dontabhaktuni, A.
Loizos, N.
Nippgen, J.
Amato, R.

January 2014

PURPOSE: The platelet-derived growth factor receptor (PDGFR) has an important role in tumorigenesis ...

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

Tran, Ben
Carvajal, Richard D
Marabelle, Aurelien
Patel, Sandip Pravin
LoRusso, Patricia M
Rasmussen, Erik
Juan, Gloria
Upreti, Vijay V
Beers, Courtney
Ngarmchamnanrith, Gataree
Schoffski, Patrick

September 2018

BACKGROUND: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, p...

A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors

L.W. Goff
R.B. Cohen
J.D. Berlin
F.G. De Braud
A. Lyshchik
C. Noberasco
F. Bertolini
M. Carpentieri
C.G. Stampino
A. Abbattista
E. Wang
H. Borghaei

May 2016

Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II do...

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

Wagner, AJ
Kindler, H
Gelderblom, H
Schöffski, Patrick
Bauer, S
Hohenberger, P
Kopp, H-G
Lopez-Martin, JA
Peeters, M
Reichardt, P
Qin, A
Nippgen, J
Ilaria, RL
Rutkowski, P

March 2017

This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously...

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Aftimos, Philippe
Van Rompaey, Luc
Michotte, Jean-Marie
Silence, Karen
Hultberg, Anna
Gandini, Domenica
De Haard, Hans
Ribrag, Vincent
Peeters, Michel
Thibault, Alain
Leupin, Nicolas
Rolfo, Christian
Awada, Ahmad
Rottey, Sylvie
Offner, Fritz
Bron, Dominique
Maerevoet, Marie
Soria, Jean-Charles
Moshir, Mahan
Dreier, Torsten

November 2017

Purpose: The purpose of this study was to evaluate safety, pharmacokinetics, pharmacodynamics, and p...

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.

Naing, Aung
Gainor, Justin F
Gelderblom, Hans
Forde, Patrick M
Butler, Marcus O
Lin, Chia-Chi
Sharma, Sunil
Ochoa de Olza, Maria
Varga, Andrea
Taylor, Matthew H
Schellens, Jan H M
Wu, Hongqian
Sun, Haiying
Silva, Antonio P
Faris, Jason
Mataraza, Jennifer
Cameron, Scott
Bauer, Todd M

March 2020

BACKGROUND: Spartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD...

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Reynolds, Kerry Lynn
Bedard, Philippe L
Lee, Se-Hoon
Lin, Chia-Chi
Tabernero, Josep
Alsina, Maria
Cohen, Ezra
Baselga, José
Blumenschein, George
Graham, Donna M
Garrido-Laguna, Ignacio
Juric, Dejan
Sharma, Sunil
Salgia, Ravi
Seroutou, Abdelkader
Tian, Xianbin
Fernandez, Rose
Morozov, Alex
Sheng, Qing
Ramkumar, Thiruvamoor
Zubel, Angela
Bang, Yung-Jue

December 2017

BackgroundHuman epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal grow...

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Jennifer Mataraza
Todd M Bauer
Justin F Gainor
Sunil Sharma
Maria Ochoa de Olza
Jan H M Schellens
Hongqian Wu
Haiying Sun
Antonio P Silva
Jason Faris
Scott Cameron

June 2020

BackgroundSpartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1...

A Phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Seroutou, Abdelkader
Tian, Xianbin
Fernandez, Rose
Morozov, Alex
Sheng, Qing
Ramkumar, Thiruvamoor
Zubel, Angela

January 2017

Background: Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal g...

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.

Coveler, Andrew L
Smith, David C
Phillips, Tycel
Curti, Brendan D
Goel, Sanjay
Mehta, Amitkumar N
Kuzel, Timothy M
Markovic, Svetomir N
Rixe, Olivier
Bajor, David L
Gajewski, Thomas F
Gutierrez, Martin
Lee, Hun Ju
Gopal, Ajay K
Caimi, Paolo
Heath, Elisabeth I
Thompson, John A
Ansari, Sahar
Jacquemont, Celine
Topletz-Erickson, Ariel
Zhou, Peigen
Schmitt, Michael W
Grilley-Olson, Juneko E

June 2023

BACKGROUND: SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG METHODS: SEA-C...

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

Gan, H.K.
Millward, M.
Jalving, M.
Garrido-Laguna, I.
Lickliter, J.D.
Schellens, J.H.
Lolkema, M.P.
Herpen, C.M.L. van
Hug, B.
Tang, L.
O'Connor-Semmes, R.
Gagnon, R.
Ellis, C.
Ganji, G.
Matheny, C.
Drilon, A.

January 2021

BACKGROUND: GSK2849330, an anti-HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signal...

A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors

Hellmann, Matthew David
Shimizu, Toshio
Doi, Toshihiko
Hodi, F. Stephen
Rottey, Sylvie
Aftimos, Philippe Georges
Liu, Zhuqing Tina
de Mendizabal, Nieves Velez
Szpurka, Anna M.
Piao, Yongzhe
Vangerow, Burkhard
Gandhi, Leena
Leow, Ching Ching

January 2019

TPS2654 Background: Programmed cell death 1 immune checkpoint inhibitors (anti-PD-1, anti-PD-L1) ha...

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Ben Tran
Richard D. Carvajal
Aurelien Marabelle
Sandip Pravin Patel
Patricia M. LoRusso
Erik Rasmussen
Gloria Juan
Vijay V. Upreti
Courtney Beers
Gataree Ngarmchamnanrith
Patrick Schöffski

September 2018

Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokin...

Short Communication

Abstract

Extracted data

Short Communication

Abstract

Extracted data

Related items

Related items